Table 2 Ongoing trials for unresectable stage III NSCLC patients that may change clinical practice in 5Â years
From: Emerging evidence and treatment paradigm of non-small cell lung cancer
Agents | Agent type | Control arm | Status | Chemo-radiotherapy | NCT/Name | Sample size | Primary endpoint |
|---|---|---|---|---|---|---|---|
Arm1:TQB2450 + Anlotinib Arm2: TQB2450 | PD-L1 inhibitor | Placebo | Phase III | cCRT/sCRT | NCT04325763 | 315 | PFS |
Arm1: Durvalumab + Oleclumab; Arm2: Durvalumab + Monalizumab | PD-L1 inhibitor; CD73 inhibitor; NKG2A inhibitor | Durvalumab + Placebo | Phase III | cCRT | NCT05221840 (PACIFIC-9) | 999 | PFS |
Durvalumab + Domvanalimab | PD-L1 inhibitor; TIGIT inhibitor | Durvalumab + Placebo | Phase III | cCRT | NCT05211895 (PACIFIC-8) | 860 | PFS |
Durvalumab | PD-L1 inhibitor | Placebo | Phase III | cCRT/sCRT | NCT03706690 (PACIFIC-5) | 407 | PFS |
Durvalumab + cCRT → durvalumab | PD-L1 inhibitor | Placebo | Phase III | cCRT | NCT03519971 (PACIFIC-2) | 328 | PFS |
Arm1: Pembrolizumab + cCRT → pembrolizumab; Arm2:Pembrolizumab + cCRT →  pembrolizumab + Olaparib | PD-1 inhibitor; PARP inhibitor | Durvalumab | Phase III | cCRT | NCT04380636 (KEYLYNK-012) | 870 | PFS; OS |
Pembrolizumab + vibostolimab + cCRT → pembrolizumab + vibostolimab; | PD-1 inhibitor; TIGIT inhibitor | Durvalumab | Phase III | cCRT | NCT05298423 (KEYVIBE-006) | 784 | PFS; OS; PFS + OS (PD-L1 ≥ 1%); |
Arm1: Nivolumab + cCRT →  nivolumab + ipilimumab Arm2: Nivolumab + cCRT →  nivolumab | PD-1 inhibitor; CTLA-4 inhibitor | Durvalumab | Phase III | cCRT | NCT04026412 (CheckMate73L) | 888 | PFS |
Atezolizumab + tiragolumab | PD-L1 inhibitor; TIGIT inhibitor | Durvalumab | Phase III | cCRT | NCT04513925 (SKYSCRAPER-03) | 800 | PFS |
Osimertinib | EGFR-TKI | Placebo | Phase III | cCRT/sCRT | NCT03521154 (LAURA) | 216 | PFS |
Almonertinib | EGFR-TKI | Placebo | Phase III | cCRT/sCRT | NCT04951635 | 150 | PFS |
Arm1: Alectinib Arm2: Entrectinib Arm3: Pralsetinib | ALK-TKI; ROS1-TKI; RET-TKI | Durvalumab | Phase I-III | cCRT/sCRT | NCT05170204 | 320 | PFS |
MRD+: Durvalumab+ Chemotherapy; MRD−: Durvalumab | PD-L1 inhibitor | – | Phase II | cCRT | NCT04585490 | 48 | The change of ctDNA (MRD+) due to the addition of chemotherapy |